REGENTIS BIOMATERIALS LTD.
RGNT · Orthopedic, Prosthetic & Surgical Appliances & Supplies · EDGAR filings ↗
Grade
D49Pre-revenue regenerative-medicine (knee-cartilage device) company, recently IPO'd, with deeply negative returns.
Strengths
- December 2025 IPO repaid most debt, improving the balance sheet
- CE-marked lead product (GelrinC) provides a regulatory foothold in Europe
Risks
- No revenue to date; ROE -2.9 (12.9th pct), ROA -1.8 (18.8th pct)
- Net income deteriorated sharply YoY (3.1st pct); ~$7.4M cash against ongoing pivotal-study spend
- Dependent on third-party CROs/clinical sites and future strategic partners; no commercial partner in place
Key metrics
Return on equity
-287.7%
Return on assets
-179.2%
Net-income growth
-384.3%
Tangible book value
$5M
Cash & investments
$7M
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-02-24 | 2025-12-31 | 0001213900-26-019917 ↗ |